Physician profile
Mark A Ashby
NPI 1063417616
$2,229.28
in general payments reported to CMS, 2019-2025
18 companies · $759 in 2025
The $759 reported for 2025 was more than what 77% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $303 · 2020: $146 · 2021: $478 · 2022: $114 · 2023: $217 · 2024: $211 · 2025: $759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,187.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $542.11 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $407.22 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Sunovion Pharmaceuticals INC. | $224.59 | 2019-2021 | |
| Abbvie INC. | $159.95 | 2022-2024 | Vraylar |
| Axsome Therapeutics, INC. | $154.61 | 2025 | Auvelity |
| Alkermes, INC. | $123.17 | 2019-2025 | Aristada, Lybalvi |
| Ironshore Pharmaceuticals INC. | $118.89 | 2021 | |
| Vanda Pharmaceuticals INC. | $79.63 | 2025 | Fanapt |
| Neurocrine Biosciences, INC. | $69.33 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $66.72 | 2023-2024 | Austedo Xr |
| Allergan, INC. | $65.44 | 2019-2020 | |
| Eisai INC. | $51.06 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.05 | 2021-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $41.09 | 2025 | Cobenfy |
| Tempus Ai, INC | $29.68 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $16.25 | 2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $15.59 | 2019 | |
| Almatica Pharma LLC | $14.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Ashby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.